MyFinsight
Home
Blog
About
Proceeds from offering of
common stock, net of...
$117,499K
(1263.26%↑ Y/Y)
Proceeds from exercise of
stock options
$36K
Net cash provided by
financing activities
$117,535K
(1867.11%↑ Y/Y)
Net increase
(decrease) in cash, cash...
$58,167K
(730.84%↑ Y/Y)
Canceled cashflow
$59,368K
Stock-based compensation
expense
$2,193K
(-61.14%↓ Y/Y)
Right-of-use assets
-$1,533K
(82.37%↑ Y/Y)
Interest related to sale
of future revenues
$1,061K
(-74.95%↓ Y/Y)
Depreciation
$416K
(-88.91%↓ Y/Y)
Loss on disposal of
fixed assets
-$111K
(94.94%↑ Y/Y)
Net cash provided by
(used in) investing...
-$29,800K
(-130.09%↓ Y/Y)
Net cash used in
operating activities
-$29,568K
(69.83%↑ Y/Y)
Canceled cashflow
$5,314K
Purchases of marketable
securities
$29,694K
Purchases of property and
equipment
$106K
(-7.02%↓ Y/Y)
Net loss
-$18,230K
(85.90%↑ Y/Y)
Deferred revenue
-$8,194K
(-31.72%↓ Y/Y)
Accrued expenses
-$4,035K
(-277.68%↓ Y/Y)
Prepaid expenses and
other current assets
$1,871K
(347.61%↑ Y/Y)
Operating lease
liabilities
-$1,637K
(81.91%↑ Y/Y)
Other non-current
liabilities
-$454K
(-123.76%↓ Y/Y)
Net accretion of
discounts on marketable...
$142K
(-83.10%↓ Y/Y)
Accounts receivable
$133K
(100.85%↑ Y/Y)
Other non-cash items
$128K
(-67.18%↓ Y/Y)
Accounts payable
-$58K
(-104.71%↓ Y/Y)
Back
Back
Cash Flow
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)
source: myfinsight.com